4//SEC Filing
Griffin Deborah A 4
Accession 0001209191-20-020167
CIK 0000818686other
Filed
Mar 18, 8:00 PM ET
Accepted
Mar 19, 8:09 AM ET
Size
9.5 KB
Accession
0001209191-20-020167
Insider Transaction Report
Form 4
Griffin Deborah A
Chief Accounting Officer
Transactions
- Exercise/Conversion
Ordinary Shares
2020-03-17+944→ 944 total - Sale
Ordinary Shares
2020-03-17$7.16/sh−944$6,762→ 0 total - Exercise/Conversion
Restricted Share Units
2020-03-17−944→ 0 total→ Ordinary Shares (944 underlying)
Footnotes (4)
- [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- [F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.1600 to $7.1850, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F4]Restricted share units were granted on March 17, 2016, with 943 vesting on each of March 17, 2018 and March 17, 2019 and 944 vesting on March 17, 2020.
Documents
Issuer
TEVA PHARMACEUTICAL INDUSTRIES LTD
CIK 0000818686
Entity typeother
Related Parties
1- filerCIK 0001719115
Filing Metadata
- Form type
- 4
- Filed
- Mar 18, 8:00 PM ET
- Accepted
- Mar 19, 8:09 AM ET
- Size
- 9.5 KB